Spruce Biosciences, Inc.
As of Oct 22, 2026, Spruce Biosciences is in Stage 1, the basing phase, now in week 8 (since Aug 27, 2026). It closed at $46.00, 67.3% below its 52-week high and below its 200-day average, which is falling.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SPRB early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SPRB among Biotechnology412th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …412 | SPRB | Stage 1 · wk 8 | 17 | −6.9% |
Spruce Biosciences: quick answers
What stage is Spruce Biosciences in?
As of Oct 22, 2026, Spruce Biosciences (SPRB) is in Stage 1, the basing phase. It entered Stage 1 on Aug 27, 2026 and is in week 8. What the four stages mean
Is Spruce Biosciences in an uptrend?
Not yet. Spruce Biosciences is in Stage 1, a base that can come before an uptrend. It trades 18.9% below its 200-day average, which is falling.
How far is Spruce Biosciences from its 52-week high?
Spruce Biosciences closed at $46.00 on Oct 22, 2026, 67.3% below its 52-week high of $140.53. Its 52-week low is $38.98.
How has Spruce Biosciences performed over the past year?
As of Oct 22, 2026, Spruce Biosciences is down 64.5% over the past year and down 49.3% so far in 2026.
Which sector and industry is Spruce Biosciences in?
Spruce Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.